The major driving factors for hematology and oncology diagnostics market include increasing incidences of blood related disorders and cancers.
The global interventional oncology market
is projected to reach USD 2.9 billion by 2024 from USD 2.0 billion in
2019, at a CAGR of 6.8% from 2019 to 2024. The growth of this market is
primarily driven by the rising preference for minimally invasive
procedures, expansion of the target patient population, increasing
public-private funding and government support for cancer research,
technological advancements in the field of interventional oncology, and increasing government investments and funding for interventional oncology and related cancer research.
The global hematology diagnostics
market size was estimated at USD 5.96 billion in 2017. It is
anticipated to expand at a CAGR of 5.85% over the forecast period.
Nearly 1 million new cases of blood cancer
are expected to be diagnosed by 2020, which is anticipated to account
for nearly 6.0% of all new cancer. Furthermore, a significant number of
the world population have different hemoglobinopathies. High prevalence
of blood disorders, such as thalassemia is anticipated to boost the demand for hematology testing.
To explore more about hematology/ oncology, PS: http://bit.ly/2xaW3zT
Source of info: https://www.grandviewresearch.com/industry-analysis/hematology-diagnostics-market | https://www.marketresearch.com/MarketsandMarkets-v3719/Interventional-Oncology-Product-Radiofrequency-microwave-12290878/
No comments:
Post a Comment